In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).

[1]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[2]  J. Butler,et al.  The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  U. Elkayam,et al.  Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure. , 2004, The American journal of cardiology.

[4]  G. Fonarow,et al.  The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. , 2003, Reviews in cardiovascular medicine.

[5]  Christopher M O'Connor,et al.  Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. , 2003, Journal of the American College of Cardiology.

[6]  T. LeJemtel,et al.  Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. , 2002, American heart journal.

[7]  J. Tu,et al.  Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. , 2002, Archives of internal medicine.

[8]  Robert M Califf,et al.  Early statin initiation and outcomes in patients with acute coronary syndromes. , 2002, JAMA.

[9]  Daniel Levy,et al.  Long-term trends in the incidence of and survival with heart failure. , 2002, The New England journal of medicine.

[10]  A. Burger,et al.  Intravenous nesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure. , 2002, The American journal of cardiology.

[11]  James B. Young.  Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial , 2002 .

[12]  R. Califf,et al.  Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. , 2002, JAMA.

[13]  J. Ghali,et al.  Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. , 2002, Journal of the American College of Cardiology.

[14]  E. Antman,et al.  ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .

[15]  M. Lauer,et al.  Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: A propensity analysis. , 2001, JAMA.

[16]  C. O'connor,et al.  Inotropic therapy for heart failure: an evidence-based approach. , 2001, American heart journal.

[17]  M. Lauer,et al.  Aspirin Use and All-Cause Mortality Among Patients Being Evaluated for Known or Suspected Coronary Artery Disease , 2001 .

[18]  J. O’Connell,et al.  The economic burden of heart failure , 2000, Clinical cardiology.

[19]  Orton,et al.  INTRAVENOUS NESIRITIDE, A NATRIURETIC PEPTIDE, IN THE TREATMENT OF DECOMPENSATED CONGESTIVE HEART FAILURE , 2000 .

[20]  P. Rosenbaum,et al.  Invited commentary: propensity scores. , 1999, American journal of epidemiology.

[21]  R. Califf,et al.  Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). , 1999, American heart journal.

[22]  H. Eiskjaer,et al.  Renal effects of brain natriuretic peptide in patients with congestive heart failure. , 1999, Clinical science.

[23]  R. D'Agostino.  Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. , 2005, Statistics in medicine.

[24]  L. Stevenson.  Inotropic therapy for heart failure. , 1998, The New England journal of medicine.

[25]  P. Binkley,et al.  Parenteral inotropic support for advanced congestive heart failure. , 1998, Progress in cardiovascular diseases.

[26]  W. Abraham,et al.  Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. , 1998, Journal of cardiac failure.

[27]  Donald Rubin,et al.  Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.

[28]  Y Wang,et al.  Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. , 1997, Archives of internal medicine.

[29]  D. Heitjan,et al.  Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. , 1996, Circulation.

[30]  D. Mancini,et al.  Rationale for treatment of patients with chronic heart failure with adrenergic blockade. , 1996, JAMA.

[31]  M. Dolgin,et al.  Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels , 1994 .

[32]  H. Nawrath,et al.  Pharmacology of bipyridine phosphodiesterase III inhibitors. , 1991, European journal of anaesthesiology. Supplement.

[33]  Wolfgang Kruse,et al.  Early Readmission of Elderly Patients with Congestive Heart Failure , 1991, Journal of the American Geriatrics Society.

[34]  S. Gottlieb,et al.  Prevention and reversal of nitrate tolerance in patients with congestive heart failure. , 1987, The New England journal of medicine.

[35]  T. LeJemtel,et al.  Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure. , 1986, Journal of the American College of Cardiology.

[36]  D. Baim,et al.  Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. , 1986, Circulation.

[37]  D. Rubin,et al.  Reducing Bias in Observational Studies Using Subclassification on the Propensity Score , 1984 .

[38]  Leo Breiman,et al.  Classification and Regression Trees , 1984 .

[39]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .